Atara Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statem ents of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net income (loss) | $32,688 | $(85,403) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Stock-based compensation expense | 9,752 | 27,001 |
| Non-cash operating lease expense | 4,996 | 12,126 |
| Depreciation and amortization expense | 2,116 | 5,051 |
| Accretion of liability related to sale of future revenues | 3,578 | 4,109 |
| Amortization (accretion) of investment premiums (discounts) | 259 | (240) |
| Loss on impairment of lease right-of-use asset | 4,130 | — |
| Gain on derecognition of lease liabilities upon contract assignment | (3,818) | — |
| Other non-cash items, net | 94 | (402) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 229 | 32,626 |
| Inventories | 10,655 | (4,434) |
| Other current assets | 6,170 | (1,227) |
| Other assets | 15 | 19 |
| Accounts payable | (4,240) | 687 |
| Accrued compensation | (5,318) | (4,930) |
| Accrued research and development expenses | (7,902) | (9,380) |
| Other current liabilities | (4,516) | (12,504) |
| Deferred revenue | (94,376) | (20,303) |
| Operating lease liabilities | (5,453) | (11,051) |
| Other long-term liabilities | 1 | (462) |
| Net cash used in operating activities | (50,940) | (68,717) |
| Investing activities | ||
| Purchases of short-term investments | (7,885) | (19,665) |
| Proceeds from maturities and sales of short-term investments | 25,085 | 28,535 |
| Purchases of property and equipment | — | (246) |
| Proceeds from sale of property and equipment | 948 | — |
| Net cash provided by investing activities | 18,148 | 8,624 |
| Financing activities | ||
| Proceeds from sale of common stock and pre-funded warrants in registered direct offerings, net | 14,843 | 50,603 |
| Proceeds from issuance of common stock through ATM facilities, net | 1,471 | 9,348 |
| Proceeds from employee stock awards | 35 | 230 |
| Principal payments on finance lease obligations | (250) | (892) |
| Other financing activities, net | (1) | (7) |
| Net cash provided by financing activities | 16,098 | 59,282 |
| Decrease in cash, cash equivalents and restricted cash | (16,694) | (811) |
| Cash, cash equivalents and restricted cash at beginning of period | 25,176 | 25,987 |
| Cash, cash equivalents and restricted cash at end of period | $8,482 | $25,176 |
| Supplemental cash flow disclosure | ||
| Cash paid for interest | $286 | $685 |
| Cash paid for income taxes | $190 | $24 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.